Artios in-licenses experimental cancer drug
Cambridge, UK-based Artios Pharma has exercised an option to in-license the first nuclease drug development programme from its research alliance with Masaryk University in the Czech Republic.
Read More
Tag: DNA Damage Response
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
